Today, April 18, 2018, the AGM of Hemfosa Fastigheter AB adopted the income statements and balance sheets for the Parent Company and the Group for the 2017 fiscal year. The Board of Directors and the CEO were also discharged from liability for the 2017 fiscal year.
Dividends
The AGM resolved to pay a dividend of SEK 4.80 per ordinary share for the 2017 fiscal year, with quarterly payment of SEK 1.20 per ordinary share. The record dates for the distribution of dividends on the ordinary share are April 20, 2018, July 10, 2018, October 10, 2018 and January 10, 2019.
The AGM also resolved to pay a dividend of SEK 10.00 per preference share, with quarterly payment of SEK 2.50 per preference share. The record dates for the distribution of dividends on the preference share are July 10, 2018, October 10, 2018, January 10, 2019 and April 10, 2019.
The dividend payments according to the above total SEK 867,095,585.
Moreover, the AGM resolved that the new ordinary shares that may be issued with the support of the authorisation granted to the Board to decide to issue new ordinary shares will provide entitlement to dividends, in accordance with the above, as of the day on which these shares have been entered into the share register maintained by Euroclear Sweden AB. Assuming that the authorisation is exercised in full, the dividend on additional ordinary shares will amount to a maximum of SEK 75,709,560.
Board of Directors and Auditor
The AGM resolved to elect the Board of Directors and pay them fees in accordance with the Nomination Committee’s proposal and re-elected the Board members Bengt Kjell, Jens Engwall, Gunilla Högbom, Anneli Lindblom, Per-Ingemar Persson, Caroline Sundewall and Ulrika Valassi. For further information regarding members of the Board, please refer to the company’s website www.hemfosa.se.
The registered accounting firm KPMG AB was re-elected as the company’s auditor for the period until the end of the next AGM. KPMG AB has announced that Björn Flink will be appointed Auditor in Charge.
Resolution regarding authorisation to resolve upon new issue of ordinary shares
The AGM resolved to authorise the Board of Directors on one or more occasions during the period until the end of the next AGM, with or without deviation from the shareholders’ pre-emption right, to decide on the issuance of new ordinary shares. The total number of ordinary shares that may be issued pursuant to the authorisation may not exceed 10 percent of the total number of ordinary Hemfosa shares, at the time of exercising the authorisation. Such new ordinary shares shall be issued at a subscription price corresponding to market terms and payment can be made, except for payment in cash, by assets contributed in kind or by set-off.
Resolution regarding authorisation to resolve upon acquisition and transfer of ordinary shares in the company
The AGM resolved to authorise the Board of Directors to, at on one or more occasions for the period until the end of the next AGM, acquire ordinary shares in the company so that, as a maximum, the company’s holding following the acquisition does not exceed 10 percent of all the shares in Hemfosa at any time. Acquisitions may only be conducted at Nasdaq Stockholm and at a price that is within the registered range for the share price prevailing at any time, that is, the range between the highest bid price and the lowest ask price.
The AGM also resolved to authorise the Board of Directors to, at on one or more occasions for the period until the end of the next AGM, resolve upon transfers of the company’s ordinary shares in accordance with the Board’s proposal.
Furthermore, the AGM resolved on guidelines for remuneration of the company’s senior executives in accordance with the Board’s proposal.
For further information, please contact:
Jens Engwall, CEO, [email protected], mobile +46 70 690 65 50, office +46 8 448 04 80